acterize the outcomes. Few studies have been validated in subsequent analyses at other institutions. 19 Thus, controversy exists regarding standard treatment, including the need for maximal resection and the timing of radiation therapy, 1, 3, 7, 15 as significant variability in treatment of LGG exists between institutions. 1 To address these issues, we recently presented an LGG scoring system based on the retrospective analysis of a single institutional study population. 8 The aim of the scoring system was to derive an easy-to-use and reliable method for prognosticating outcomes preoperatively. Others have also shown that preoperative variables play an important role in prognosis. 1 In our earlier study, multivariate Cox proportional hazard modeling demonstrated that 4 variables (age at diagnosis > 50 years, KPS score ≤ 80, location of tumor in presumed eloquent cortex, and maximum diameter of tumor > 4 cm) were associated with lower survival times.
The finding that age, 1, 17, 18, 22 KPS score, 1, 17 and tumor size 22 are important prognostic factors is consistent with the results of prior studies. However, prior authors have not taken into consideration tumor location relative to eloquent cortex that affects tumor resectability and neurological function. Additional benefits of our scoring system are the ease of use, which is reflected in the high degree of interobserver reliability and the ability to be used preoperatively at the time of radiographic diagnosis. Our hope was to develop a scoring system that could be accurately applied to help physicians predict those patients with LGGs associated with a good and poor prognosis before any intervention takes place. Subsequent treatment decisions might then be influenced by the grouping of patients into different scoring groups. This is fundamentally important for 2 reasons: 1) to provide a practical tool for clinicians to use for advising patients about long-term outcomes early in the management and 2) to provide a method to stratify patient groups in future research studies on the outcomes of surgery and/or adjuvant therapy. The precise roles of surgery and radiation therapy, although both are commonly practiced, are still unclear, and these roles are unlikely to be resolved unless pretreatment-related factors are clearly identified. We believe that this scoring system does not exclude postoperative factors, but instead can be added to them powerfully.
One significant limitation of our previously proposed scoring system was whether our results could generalize to other institutions where different management strategies or patient demographics might exist, as our survival estimates were drawn from a single institutional patient cohort. Therefore, to validate the UCSF LGG Scoring System, we analyzed a large population of patients with LGGs treated at 3 external institutions for the presence of the previously identified prognostic factors and subsequent OS and PFS.
Methods
Three institutions, UU, UCLA, and TWH, provided retrospective analyses of 256 patients with confirmed LGGs. All patients had histologically confirmed WHO Grade II low-grade infiltrative gliomas 16 diagnosed after 1995 (since the introduction of MR imaging). To generate scores based on the UCSF LGG Scoring System, preoperative clinical and radiographic data were analyzed by individuals at the different institutions. Collaborators were given copies of the prior manuscript and detailed instructions on how to calculate the LGG score. The institutions provided data on the individual components of the scoring system: age > 50 years, KPS score ≥ 80, maximum diameter of tumor > 4 cm, and location of the tumor in the eloquent cortex.
The clinical variables, age, and KPS score were derived from hospital charts. Age was dichotomized as > 50 years and ≤ 50 years. Likewise, KPS score was dichotomized as > 80 and ≤ 80. Tumor size was determined using digital caliper measurements of the maximum tumor diameter in any dimension on FLAIR or T2-weighted MR images. Size was then dichotomized as > 4 cm and ≤ 4 cm. Lastly, the presumed eloquent cortex was defined as preoperative MR imaging evidence of tumor in the sensorimotor strip (pre-and postcentral gyri), dominant hemisphere perisylvian language cortex (superior temporal, inferior frontal, and inferior parietal areas), the basal ganglia/internal capsule, thalamus, and calcarine visual cortex. A presumed eloquent location was dichotomized as yes or no. The presence of each variable was assigned 1 point. The LGG score was then based on the sum of the presence of each variable (range 0-4).
Time to death and time to progression were also provided by the institutions. Overall survival was defined as the time interval between date of surgery and the date of death or date that the patient was last known to be alive. Progression of disease was defined as an unequivocal increase in FLAIR/T2 signal abnormality and/or newly detected areas of contrast enhancement on follow-up MR imaging compared with the baseline postoperative MR obtained within 3 days of surgery. Progression-free survival was defined as the time interval between date of surgery and date of MR imaging on which the first progression event was detected or the date of the last known MR imaging with no evidence of disease progression (whichever occurred first).
Statistical Analysis
Differences in the categorical variables between the previously published UCSF data (construction set) and those from the current study (validation set) were compared by chi-square test. Statistical analysis of the 4 prognostic factors for time to death and time to progression was done using Cox proportional hazard modeling. Kaplan-Meier estimates were generated to illustrate the time-to-event curves. Differences in time to event between individual scores were compared by the log-rank test. Our original intent was to validate the scoring system for the cohort from each independent institution; however, all patients were finally combined because there needed to be at least 200 per group for meaningful comparison with the construction set. Analyses were carried out using SPSS (SPSS, Inc.) and JMPIN 4.0.4 (SAS Institute Inc.).
Results

Study Population
Data from a total of 256 patients were gathered from 3 external institutions, including TWH (130 cases), UU (88 cases), and UCLA (38 cases). The median duration of follow-up for those still alive at last visit was 63 months (5.3 years). The demographics, tumor characteristics, progression, and survival data from the 3 institutions are summarized in Table 1 . During the follow-up period, the observed number of mortality events was 88 (34%) and the number of disease progression events was 154 (60%). Progressionrelated data were missing from 1 patient. The OS was 120 months (range 1-330) and the median PFS was 48 months (range 1-277). The median OS at UU was 148 months (range 3-330 months); at UCLA it was not reached (range 1-120 months); and at TWH it was 96 months (range 10-204 months). The median PFS at UU was 60 months (range 2-277 months), at UCLA it was 48 months (range 1-81 months), and at TWH it was 46 months (range 3-240 months). No significant differences in OS or PFS between institutions were observed (p = 0.07 and p = 0.23, respectively, log-rank test).
Comparison of UCSF Construction Set to External Institution Validation Set
To assess any significant differences between the construction and external validation sets, the patient and tumor characteristics of the 2 sets were compared ( Table  2) . 8 The sets did not significantly differ with respect to patient age > 50 years (p = 0.15, chi-square test) or KPS score ≤ 80 (p = 0.71, chi-square test). A greater proportion of patients in the UCSF cohort had tumors located in presumed eloquent cortex compared with others (61.9 vs 50%, respectively; p = 0.005, chi-square test). A greater proportion of patients in the validation cohort had tumors > 4 cm compared with the UCSF cohort (61.7 vs 42.7%, respectively, p < 0.0001, chi-square test). Despite these differences, data in both the construction and validation cohort sets were overall very similar.
Validation
Cox proportional hazard modeling was used to determine if the 4 previously published predictors of OS and PFS 8 were also predictors of these factors in the validation set ( Table 3 ). The 4 components of the UCSF LGG scale were associated with shorter OS: eloquent location (HR 2.04, The scoring system was then applied to the validation set. Score Groups 3 and 4 were combined because of the small number of patients with a score of 4 (14 patients). The differences in OS and PFS were highly significant between score groups (p < 0.0001, log-rank test). The Kaplan-Meier estimated median OS for the validation set based on score (Fig. 1 upper) was as follows: Score 0, 184 months (95% CI not determined given length of followup); Score 1, 120 months (95% CI 108-148); Score 2, 156 months (95% CI 89-180); and Score 3/4, 60 months (95% CI 47-75). Differences between individual score groups were then analyzed and score groups 0 and 1 and 2 and 3/4 were found to be statistically different (Table 4 ; p = 0.04 and p < 0.0001, log-rank test, respectively). Score Groups 1 and 2 were not significantly different (Table 4 ; p = 0.92, log-rank test,).
The scoring system was then used to estimate PFS. The Kaplan-Meier estimated median PFS for the validation set based on LGG score (Fig. 1 lower) was as follows: Score 0, 72 months (95% CI 54-133); Score 1, 60 months (95% CI 52-81); Score 2, 56 months (95% CI 35-60); and Score 3/4, 30 months (95% CI 26-41). Log-rank analysis showed that Groups 0 and 1 and Groups 1 and 2 were not significantly different (p = 0.23 and p = 0.25, respectively); however, Groups 2 and 3/4 were statistically different (p = 0.0009) ( Table 5) .
Combined Construction and Validation Set Data
Lastly, the validation set was analyzed in combination with the previously published UCSF patient group (construction set) 8 to determine the most accurate survival estimates from a large patient population (537 patients). Kaplan-Meier OS and PFS curves are depicted in Fig. 2 upper and lower, respectively. The estimated median OS was as follows: Score 0, 194 months (95% CI 162-not applicable); Score 1, 148 months (95% CI 128-not applicable); Score 2, 120 months (95% CI 97-154); Score 3, 60 months (95% CI 48-75); and Score 4, 59 (95% CI 26-88). The differences in OS estimates between the 0 and 1, 1 and 2, and 2 and 3/4 score groups were highly significant (log-rank test, p = 0.005, p = 0.0005, p < 0.0001, respectively). Estimated median PFS also decreased with increasing score; Score 0 = 108 months (95% CI 82-146); Score 1, 70 months (95% CI 64-84); Score 2, 58 months (95% CI 48-66; Score 3, 36 months (95% CI 26-46); and Score 4, 20 (95% CI 11-47). The differences in PFS estimates between the Score 0 and 1, Score 1 and 2, and Score 2 and 3/4 groups were also significant (p = 0.006, p = 0.03, p = 0.0009, respectively, log-rank test). The 5-year cumulative OS probabilities decreased with increasing score: Score 0, 0.98; Score 1, 0.90; Score 2, 0.81; Score 3, 0.53; and Score 4, 0.46 (Table 6 ). Likewise, the 5-year cumulative PFS probabilities decreased with increasing score: Score 0, 0.75; Score 1, 0.67; Score 2, 0.47; Score 3, 0.23; and Score 4, 0.07 (Table 6 ).
Discussion
Using a large, multiinstitutional cohort, we validated our previously proposed prognostic scoring system for patients with LGG. 8 Four variables were confirmed to be predictive of survival in a multivariate analysis-1) location of tumor in eloquent cortex, 2) KPS score ≤ 80, 3) age > 50 years, and 4) maximum tumor diameter > 4 cm-and were applied to a set of 256 patients at 3 external institutions and analyzed for OS and PFS durations. We found that the scoring system based on these factors was able to predict both OS and PFS in the validation set of patients.
An advantage of the current study is that the patient data were compiled from a large sample derived from multiple institutions. With respect to age and preoperative KPS status, the cohort was not significantly different from the construction set. However, tumors in the validation set were less likely to be located in the eloquent cortex, which most likely represents a difference in referral patterns to hospitals that specialize in functional mapping. Likewise, tumors in the validation set were more likely to be larger at the time of surgery. Some institutions, for example, may have an early-observation strategy whereas others may prefer early surgical debulking. It is unlikely that the differences resulted from different interpretations of the scoring system, as we have previously shown that the scoring system has high interobserver reliability. 8 Similar to our previous study, 8 we found that age, eloquent location, tumor size, and KPS score were significantly associated with OS. In our previous study, we found that only an eloquent location was associated with shorter PFS. However, in the validation set we found that an eloquent location, size > 4 cm, and KPS status were associated with shorter time to disease progression. A large tumor size has previously been demonstrated to be associated with worse prognosis. It is suspected that the lesion's larger size may preclude complete resection, 3 may be associated with indistinct/irregular borders, carry larger disease burden, and be more likely to involve eloquent areas. Similar to the construction set, the majority of the patients in the current cohort had KPS scores > 80. Nevertheless, patients with poor KPS status had significantly worse OS and PFS, which has been shown in previous studies.
Applying the scoring system based on these factors to those in the validation set, we were able to stratify the cohort into risk groups based on score. Overall, our results paralleled those of the construction set. 8 Higher scores were associated with worse outcomes of shorter OS and PFS. Several differences were apparent, however. Unlike the construction set, we found that there was no significant difference in median OS between Score Groups 1 and 2. Likewise, there was no significant difference in PFS between and among Groups 0, 1, and 2. This outcome likely resulted from differences across institutions, as patients with favorable prognosticators possibly were more likely to have been observed or had less aggressive treatments at the time of diagnosis. We took advantage of the large number of patients available in the combined construction and validation set and analyzed the data as a single cohort to estimate the survival and disease progression from the most patients available to us. In this set, we found that there were significant differences in OS and PFS between all individual score groups. Based on these results, we believe that the scoring system has the potential for broad applicability to clinical management and research design for LGGs.
Other groups have proposed prognostic scoring systems for LGGs based on large datasets. 1, 10, 19, 21 Bauman et al. 1 used recursive partitioning analysis of a large multiinstitutional cohort to divide patients into 4 prognostic groups based on the presence of the following preoperative factors: age ≤ 40 years, KPS score ≥ 70, and absence of contrast enhancement on imaging. The scoring system proposed by Pignatti et al. 19 included the preoperative factors of age ≤ 40 years, tumor size ≥ 6 cm, tumor crossing the midline, and presence of neurological deficits before surgery. The system also included the histological subtype determined at surgery. Schuurman et al. 21 developed a scoring system for low-grade astrocytomas based on several preoperative variables (age > 40 years, presence of symptoms < 1 year, presence of a focal neurological deficit or elevated intracranial pressure, and contrast enhancement). Hamlat et al. 10 analyzed 87 patients diagnosed with oligodendrogliomas and proposed a scoring system based on the sum of 7 clinical, genetic, radiographic, and histological factors that were then stratified into 4 risk groups. To our knowledge, the current study is the first to include only data obtained since the advent of MR imaging, which is the standard imaging modality for LGGs.
The present study was designed to use preoperative factors to guide prognostication at the time of imaging diagnosis. Therefore, postoperative factors were not included. Postoperative factors and other treatment modalities can influence survival. A histological diagnosis determined definitively at surgery also correlates with prognosis in some studies, which have shown that patients with oligodendrogliomas or mixed oligoastrocytomas with oligo-dominant histology have a better prognosis than those with an astrocytic histology. 19, 22, 23, 26 However, other large studies have shown histology not to be predictive of survival. 1, 20, 27 In addition, interobserver variability in the diagnosis of oligodendrogliomas has been documented, potentially limiting its utility in prognostication. 9 Likewise, the scoring system does not include genetic alterations that are demonstrated by tissue analysis. Chromosome 1p/19q deletions are associated with longer OS and PFS in patients with low-grade oligodendrogliomas. 2, 11 This has been attributed in part to the enhanced sensitivity of these tumors to chemo-and radiotherapy. 5, 6 However, many centers do not routinely test for this genetic alteration, thereby precluding its use. More extensive resection has also been associated with improved long-term survival and disease control. 24 However, the same study of Smith et al. 24 showed that preoperative tumor volume was more strongly associated with survival, similar to the results of the current study. 24 Furthermore, we have previously shown that preoperative variables, including larger maximum diameter of the tumor and presumed eloquent location, are the strongest predictors of an incomplete resection. 8 Similarly, radiotherapy is associated with improved prognosis, although early radiotherapy or increased radiation dose is not associated with prolonged OS. 13, 22, 25 Chemotherapeutic agents, most recently temozo- lomide, appear to cause partial response in LGGs, 4 but the effect on long-term prognosis has not been rigorously tested. While our scoring system is simple and easy to apply, it is only meant to guide prognosis and clinical management and research in the preoperative setting.
Therefore, we believe and have shown that an exclusively preoperative scoring system is valid and has several applications; a prospective validation of this scoring system is currently underway. As already noted, data on the treatment of LGGs is complicated by the lack of high-quality prospective studies on which to base interventions. 15 A simple, reliable preoperative scoring system such as this will aid in the design of clinical trials and optimization of clinical management.
Conclusions
In this study, we have validated a simple and reliable preoperative scoring system that predicts long-term OS and PFS for patients with LGGs. We found that the scoring system developed at our institution could be reproducibly applied to a multiinstitutional cohort. A preoperative standardized scoring system will potentially aid in the design of evidence-based therapeutic modalities for these patients. 
